CARCINOMICS and Clinical Communications, a publication of SciPubMed, is a peer-reviewed online journal with Quarterly print on demand compilation of issues published. The journal’s full text is available online at http://www.carcinomics.org. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, ProQuest, TdNet, Wanfang Data
Wolters Kluwer and Journal/Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit www.Medknow.com/EthicalGuidelines.asp
Open Access Publication and Creative Commons Licensing
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Wolters Kluwer Medknow provides for long-term digital preservation through two primary partnerships, Portico and CLOCKSS.
Portico is a leading digital preservation service worldwide. The content is preserved as an archival version and is not publically accessible via Portico, but is provided when required under specific conditions, such as discontinuation of the collection or catastrophic failure of the website.
CLOCKSS will enable any library to maintain their own archive of content from Wolters Kluwer Medknow and other publishers, with minimal technical effort and using cheaply available hardware.
Ahead of Print policy
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Wolters Kluwer Medknow has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.
While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:
- "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
- The Editorial Board has full and final approval over the content of all advertisements.
- Advertisers will never be shown any manuscripts or other content prior to publication.
CARCINOMICS and Clinical Communications publishes outcomes of research from the fields of RNaOmics, proteomics, metabolomics, genomics, epigenomics, pharmacogenomics, etc. related to Oncology and closely related subjects. The word Carcinome was coined in a recent editorial by Dr. Gopala Kovvali (Kovvali G. Systems oncology: A new paradigm in cancer research. Journal of Carcinogenesis. 2014;13:6. doi:10.4103/1477-3163.128641) to describe an ensemble of molecular entities that is likely to regulate carcinogenesis process in a cell. The word CARCINOMICS is proposed to describe the methods and technologies used to investigate to understand the functions of the Carcinome and cancer as a systemic disease in the context of carcinogenesis, tumorigenesis and oncogenesis.
CARCINOMICS and Clinical Communications encourages publications that describe new techniques as well as the modification of the existing ones that promote various aspects of cancer research. The journal especially encourages manuscripts that deal with concepts related to emerging and yet to invented technologies. CARCINOMICS and Clinical Communications also publishes techniques and technologies that have a promise in Oncology drug discovery and development; these techniques include but not limited to structural oncology techniques as performed in the crystal, solution and in-silico environments, conjugation of drugs to antibodies and other carrier molecular vehicles, and emerging technologies that help deliver cancer drugs to the target cells. Articles related to diagnostic techniques like mammography, CT scans and other radiological and surgical techniques used in oncology will be considered.
Biomarkers are becoming an integral part of oncology drug development and have a strong impact on the diagnosis and treatment of cancers in the rapidly emerging era of personalized medicine. CARCINOMICS and Clinical Communications has a special interest in publishing articles related to oncology biomarkers.
Articles related to pharmacokinetics, pharmacodynamics, pharmacogenomics and pharmacovigilance of oncology drugs will be considered.
As the development of cancer diagnostics and therapeutics is cost and time intensive, their use in the clinical practice is a huge burden to the payers. Therefore, there is a need for discussions on the economics of development of diagnostics, discovery and development of oncology drugs as well as the economics of treatment. Articles related to these topics will be solicited and published under a special section ONCONOMICS.
The journal will also cover technical and clinical studies related to health, ethical and social issues in field of Oncology and closely related fields. Articles with clinical interest and implications will be given preference. Case reports, commentary of historical cases reports will also be considered.
Focused and insightful articles that shed light on oncology clinical trials will be considered expeditiously.